The Scientific World Journal / 2012 / Article / Tab 2

Research Article

Polyvascular Disease in Patients Presenting with Acute Coronary Syndrome: Its Predictors and Outcomes

Table 2

Management and clinical outcomes in patients with acute coronary syndrome with and without polyvascular disease.

ACS alone ( 𝑛 = 7 2 6 1 )Polyvascular disease ( 𝑛 = 4 2 8 )P value

On admission therapy %
Aspirin38740.001
Clopidogrel11230.001
𝛽 -blockers2843.50.001
ACE inhibitors24460.001
Statins29580.001
Thrombolysis*52200.001
Unfractionated heparin42400.46
LMW heparin37410.12
Glycoprotein inhibitors7.780.82

During hospitalization %
Aspirin98.5960.001
Clopidogrel76810.02
β blockers75680.002
ACE inhibitors71690.31
Statins9592.50.03
Coronary angiography39310.002
PCI2212.40.001

Discharge medications %
Aspirin96920.001
Clopidogrel68700.32
β blockers80740.01
ACE inhibitors7263.50.001
Statins92850.001

Outcomes %
Reischemia1523.40.001
Heart failure11.629.70.001
Stroke0.62.30.001
Bleedings0.60.90.31
Hospital death4.29.10.001
1-month death7.416.30.001
12-month death11.224.60.001

*ST-elevation MI, PCI: percutaneous coronary intervention.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.